Magnetic Resonance Spectroscopic Imaging Study of Prostatic Fats to Distinguish the Difference Between High and Low Risk Prostate Cancer (MRSI+RRP)

OHSU Knight Cancer Institute

Status: Completed

Conditions: Prostate Cancer

Treatments: Procedure: Magnetic Resonance Spectroscopy Imaging with rectal probe

Study type: Observational

Funder types: Other; Other U.S. Federal agency

Identifiers

NCT01780701

Log #A-17208 (Other Identifier)

8458 (Other Identifier)

PC110361 (Other Identifier)

2978 (Other Identifier)

IRB00008458

W81XWH-12-1-0168 (Other Grant/Funding Number)

Details and patient eligibility

About

A prostate cancer diagnosis starts a list of events that often leads to fast-moving treatment, thought by many to result in vast over-treatment of this disease. So, discovery of different diagnostic methods that allow clinicians to identify slow-growing from potentially fast-growing disease prior to or at the time of prostate biopsy could result in early and suitable treatment for men at greatest risk, while greatly decreasing the number of biopsies, surgical procedures, hormonal and chemotherapeutic treatments, cost, and patient worry, for those with more slow-growing disease.

Enrollment: 66 patients

Sex: Male

Ages: 21+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Prostate cancer diagnosis prior to treatment
• Age 21 years or older
• Signed informed subject consent
• Prostatectomy as planned prostate cancer treatment

Exclusion criteria

• Men who do not choose prostatectomy
• Men who have undergone any neoadjuvant therapy
• Men who have cardiac pacemakers or other implanted electronic devices
• Men who have any surgically implanted metal
• Men who have had any surgical procedure that precludes placement of endorectal probe
• Indication of dementia or memory issues listed on problem list
• Men who indicate exposure to ocular metal fragments; confirmed by positive ocular x-ray
• Men who are taking newly-prescribed (within 6 months of enrollment) lipid control medications

Trial design

66 participants in 2 patient groups

High risk prostate cancer patients

Description:

Men who have been recently diagnosed with high risk prostate cancer (Gleason score 7 and above) and who choose prostate removal for their cancer treatment will undergo Magnetic Resonance Spectroscopy Imaging (MRSI) with rectal probe at the Oregon Health \& Science University's Advanced Imaging Research Center.

Treatment:

Procedure: Magnetic Resonance Spectroscopy Imaging with rectal probe

Low risk prostate cancer patients

Description:

Men who have been recently diagnosed with low risk prostate cancer (Gleason score 7 \[3+4\] and below) and who choose prostate removal for their cancer treatment will undergo Magnetic Resonance Spectroscopy Imaging (MRSI) with rectal probe at the Oregon Health \& Science University's Advanced Imaging Research Center.

Treatment:

Procedure: Magnetic Resonance Spectroscopy Imaging with rectal probe